Payment overview · 2025
General Payments
$175.03
9 reported records · 5 companies
Healthcare provider profile · identity verified
Patrick A Litster, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HOT SPRINGS, AR · NPI 1255369666
Verified facts
What the public records show
CMS Open Payments records show Patrick A Litster, PA received $175.03 in general payments during 2025 across 9 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.24 | 32.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.11 | 30.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.53 | 19.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.27 | 9.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.88 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $175.03 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $70.38 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 434 | 93 |
| Gabapentin | Gabapentin | 330 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 66 |
| Lisinopril | Lisinopril | 243 | 56 |
| Tramadol Hcl | Tramadol Hcl | 216 | 61 |
| Omeprazole | Omeprazole | 215 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 51 |
| Losartan Potassium | Losartan Potassium | 197 | 54 |
| Metformin Hcl | Metformin Hcl | 193 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 192 | 76 |
| Alprazolam | Alprazolam | 188 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 56 |
| Furosemide | Furosemide | 156 | 44 |
| Meloxicam | Meloxicam | 152 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 37 |
| Potassium Chloride | Potassium Chloride | 139 | 39 |
| Azithromycin | Azithromycin | 136 | 111 |
| Simvastatin | Simvastatin | 135 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 39 |
| Trazodone Hcl | Trazodone Hcl | 129 | 28 |
| Lorazepam | Lorazepam | 127 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 25 |
| Montelukast Sodium | Montelukast Sodium | 101 | 24 |
| Carvedilol | Carvedilol | 100 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 30 |
| Famotidine | Famotidine | 92 | 21 |
| Prednisone | Prednisone | 92 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 18 |
| Metformin Hcl Er | Metformin Hcl | 85 | 25 |
| Clonazepam | Clonazepam | 83 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 74 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 26 |
| Glimepiride | Glimepiride | 79 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 20 |
| Pregabalin | Pregabalin | 75 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 18 |
| Diazepam | Diazepam | 70 | 17 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 14 |
| Fluconazole | Fluconazole | 51 | 22 |
| Atenolol | Atenolol | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 36 |
| Ondansetron Odt | Ondansetron | 47 | 23 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 13 |
| Allopurinol | Allopurinol | 44 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 31 |
| Estradiol | Estradiol | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 19 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 13 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $175.03 · 9 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, MOUNJARO, QULIPTA, REXULTI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error